Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Common Stock Valuation Ratios (Price Multiples) 

Microsoft Excel

Current Valuation Ratios

AbbVie Inc., current price multiples

Microsoft Excel
AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc. Pharmaceuticals, Biotechnology & Life Sciences Health Care
Selected Financial Data
Current share price (P) $206.23
No. shares of common stock outstanding 1,768,169,012
Growth rate (g) -81.55%
 
Earnings per share (EPS) $2.39
Next year expected EPS $0.44
Operating profit per share $8.53
Sales per share $34.59
Book value per share (BVPS) $-1.85
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 86.29 24.46 16.78 37.20 41.93 20.58 21.36 15.47 20.06 17.31 26.06 29.43 26.95 26.49
Price to next year expected earnings 467.74 18.14 15.28 34.30 32.18 28.31 18.81 21.69 14.71 22.98 25.08 24.64 24.13
Price to operating profit (P/OP) 24.19 20.77 11.83 28.66 32.91 17.48 22.64 13.31 10.94 21.79 22.55 27.88 21.31 20.70
Price to sales (P/S) 5.96 5.37 2.46 5.47 13.28 6.06 6.08 4.34 2.49 5.44 3.92 9.70 5.80 3.12

Based on: 10-K (reporting date: 2025-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

AbbVie Inc., historical price multiples

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Price to earnings (P/E) 94.06 79.59 63.84 22.62 22.07
Price to operating profit (P/OP) 26.37 37.26 24.34 14.78 14.21
Price to sales (P/S) 6.50 6.04 5.72 4.61 4.53
Price to book value (P/BV) 102.40 29.97 15.52 16.53

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The valuation ratios demonstrate a consistent upward trend across most metrics from 2021 through 2024, with some moderation observed in the most recent year available, 2025. This suggests increasing investor optimism or a reassessment of the company’s future earnings potential over the period. The magnitude of change varies significantly by ratio, indicating differing investor perceptions regarding the company’s earnings, operating performance, sales, and asset value.

Price to Earnings (P/E)
The Price to Earnings ratio exhibits a substantial increase, moving from 22.07 in 2021 to 94.06 in 2024. This represents a significant expansion in the multiple investors are willing to pay for each dollar of earnings. The ratio’s value in 2025 is not available for comparison, but the trend suggests continued high valuation. This increase could be driven by expectations of higher future earnings growth, reduced risk perception, or broader market conditions.
Price to Operating Profit (P/OP)
The Price to Operating Profit ratio also shows an increasing trend, though less dramatic than the P/E ratio. It rises from 14.21 in 2021 to 37.26 in 2024, before decreasing to 26.37 in 2025. This suggests that while investors are willing to pay more for each dollar of operating profit, the rate of increase slowed and even reversed in the latest period. This could indicate concerns about the sustainability of operating profitability.
Price to Sales (P/S)
The Price to Sales ratio demonstrates a steady, albeit moderate, increase from 4.53 in 2021 to 6.50 in 2025. This indicates a growing willingness to pay for each dollar of revenue generated. The consistent increase suggests that revenue growth is a key driver of valuation, and investors anticipate continued sales expansion.
Price to Book Value (P/BV)
The Price to Book Value ratio experiences the most significant relative change. Starting at 16.53 in 2021, it increases dramatically to 102.40 in 2024, and a value for 2025 is not available. This substantial increase suggests a considerable shift in investor perception regarding the company’s asset value and its ability to generate returns on those assets. The high multiple in 2024 may indicate that the market believes the company’s assets are significantly undervalued on the balance sheet, or that intangible assets are not fully reflected in book value.

Overall, the observed trends suggest a period of increasing valuation multiples, particularly for earnings and book value. The moderation in Price to Operating Profit and the lack of a 2025 value for Price to Book Value warrant further investigation to determine if this represents a temporary fluctuation or a shift in investor sentiment.

AI Ask an analyst for more


Price to Earnings (P/E)

AbbVie Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
No. shares of common stock outstanding1 1,768,169,012 1,765,354,859 1,766,473,359 1,769,399,971 1,768,753,829
Selected Financial Data (US$)
Net earnings attributable to AbbVie Inc. (in millions) 4,226 4,278 4,863 11,836 11,542
Earnings per share (EPS)2 2.39 2.42 2.75 6.69 6.53
Share price1, 3 224.81 192.87 175.75 151.31 144.03
Valuation Ratio
P/E ratio4 94.06 79.59 63.84 22.62 22.07
Benchmarks
P/E Ratio, Competitors5
Amgen Inc. 25.81 38.24 23.14 19.56 21.05
Bristol-Myers Squibb Co. 17.30 12.27 23.97 20.92
Danaher Corp. 40.93 38.12 39.09 25.65 29.94
Eli Lilly & Co. 47.45 77.63 135.24 50.08 40.66
Gilead Sciences Inc. 21.54 296.57 16.17 22.68 12.36
Johnson & Johnson 21.66 26.92 10.73 22.97 20.93
Merck & Co. Inc. 16.79 13.49 893.99 19.21 14.78
Pfizer Inc. 19.83 18.42 73.42 7.58 11.76
Regeneron Pharmaceuticals Inc. 18.19 17.76 25.99 19.68 8.37
Thermo Fisher Scientific Inc. 28.82 32.03 35.65 30.55 27.35
Vertex Pharmaceuticals Inc. 31.58 30.42 23.02 26.55
P/E Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 28.98 45.15 32.80 20.23 19.27
P/E Ratio, Industry
Health Care 28.31 38.03 30.62 21.22 21.55

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Data adjusted for splits and stock dividends.

2 2025 Calculation
EPS = Net earnings attributable to AbbVie Inc. ÷ No. shares of common stock outstanding
= 4,226,000,000 ÷ 1,768,169,012 = 2.39

3 Closing price as at the filing date of AbbVie Inc. Annual Report.

4 2025 Calculation
P/E ratio = Share price ÷ EPS
= 224.81 ÷ 2.39 = 94.06

5 Click competitor name to see calculations.


The price to earnings (P/E) ratio exhibits a significant upward trend over the observed period. While the share price consistently increased from 2021 to 2025, the earnings per share (EPS) experienced a contrasting pattern, driving substantial changes in the P/E ratio.

Share Price
The share price demonstrated consistent growth, increasing from US$144.03 in 2021 to US$224.81 in 2025. This represents a cumulative increase of approximately 56.1% over the five-year period.
Earnings Per Share (EPS)
Earnings per share initially showed a modest increase from US$6.53 in 2021 to US$6.69 in 2022. However, a substantial decline was observed in subsequent years, falling to US$2.75 in 2023, US$2.42 in 2024, and further to US$2.39 in 2025. This represents a decrease of approximately 63.3% from 2021 to 2025.
Price to Earnings (P/E) Ratio
The P/E ratio remained relatively stable between 2021 and 2022, fluctuating around 22. A dramatic increase began in 2023, rising to 63.84, and continued through 2025, reaching 94.06. This increase is primarily attributable to the decline in earnings per share while the share price continued to rise. The escalating P/E ratio suggests that investors were willing to pay a progressively higher price for each dollar of earnings, potentially reflecting expectations of future growth or a re-rating of the company’s valuation.

The divergence between share price and EPS trends resulted in a substantial increase in the P/E ratio. This suggests a shift in investor sentiment, where the market placed a greater premium on the company’s stock relative to its current earnings. Further investigation would be required to determine the underlying drivers of this valuation shift.

AI Ask an analyst for more


Price to Operating Profit (P/OP)

AbbVie Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
No. shares of common stock outstanding1 1,768,169,012 1,765,354,859 1,766,473,359 1,769,399,971 1,768,753,829
Selected Financial Data (US$)
Operating earnings (in millions) 15,075 9,137 12,757 18,117 17,924
Operating profit per share2 8.53 5.18 7.22 10.24 10.13
Share price1, 3 224.81 192.87 175.75 151.31 144.03
Valuation Ratio
P/OP ratio4 26.37 37.26 24.34 14.78 14.21
Benchmarks
P/OP Ratio, Competitors5
Amgen Inc. 21.92 21.55 19.69 13.40 16.24
Bristol-Myers Squibb Co. 12.20 13.53 18.29 19.84
Danaher Corp. 31.54 30.56 35.64 20.97 25.14
Eli Lilly & Co. 37.24 63.73 109.75 43.88 35.70
Gilead Sciences Inc. 18.29 85.65 12.05 14.21 7.76
Johnson & Johnson 22.95 18.20 17.78 17.62 18.68
Merck & Co. Inc. 14.44 11.60 138.56 15.55 15.39
Pfizer Inc. 10.82 11.92 121.63 6.64 12.74
Regeneron Pharmaceuticals Inc. 22.90 19.63 25.39 18.01 7.55
Thermo Fisher Scientific Inc. 24.94 27.65 31.16 25.30 21.07
Vertex Pharmaceuticals Inc. 29.92 28.74 17.75 22.35
P/OP Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 22.92 31.13 32.68 15.94 16.68
P/OP Ratio, Industry
Health Care 22.12 26.90 27.48 16.58 18.20

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Data adjusted for splits and stock dividends.

2 2025 Calculation
Operating profit per share = Operating earnings ÷ No. shares of common stock outstanding
= 15,075,000,000 ÷ 1,768,169,012 = 8.53

3 Closing price as at the filing date of AbbVie Inc. Annual Report.

4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 224.81 ÷ 8.53 = 26.37

5 Click competitor name to see calculations.


The price to operating profit (P/OP) ratio exhibited significant fluctuation over the five-year period. Initially, the ratio demonstrated a modest increase, followed by a substantial rise and subsequent decline. The share price consistently increased throughout the period, while operating profit per share experienced volatility.

P/OP Ratio Trend
The P/OP ratio began at 14.21 in 2021 and increased to 14.78 in 2022, indicating a relatively stable valuation in relation to operating profit. A marked increase was then observed in 2023, with the ratio reaching 24.34. This increase accelerated in 2024, peaking at 37.26. Subsequently, the ratio decreased to 26.37 in 2025, though remaining considerably higher than the levels seen in 2021 and 2022.
Share Price Movement
The share price demonstrated a consistent upward trend, increasing from US$144.03 in 2021 to US$224.81 in 2025. This consistent growth suggests positive investor sentiment over the period.
Operating Profit Per Share
Operating profit per share showed more variability. It increased slightly from US$10.13 in 2021 to US$10.24 in 2022, then decreased significantly to US$7.22 in 2023. A further decline to US$5.18 occurred in 2024, followed by a recovery to US$8.53 in 2025. This volatility in operating profit per share likely contributed to the fluctuations observed in the P/OP ratio.

The substantial increase in the P/OP ratio in 2023 and 2024, despite a declining operating profit per share, suggests that investors were willing to pay a significantly higher premium for each dollar of operating profit. The subsequent decrease in the P/OP ratio in 2025, coinciding with a partial recovery in operating profit per share, indicates a potential recalibration of valuation expectations.

AI Ask an analyst for more


Price to Sales (P/S)

AbbVie Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
No. shares of common stock outstanding1 1,768,169,012 1,765,354,859 1,766,473,359 1,769,399,971 1,768,753,829
Selected Financial Data (US$)
Net revenues (in millions) 61,160 56,334 54,318 58,054 56,197
Sales per share2 34.59 31.91 30.75 32.81 31.77
Share price1, 3 224.81 192.87 175.75 151.31 144.03
Valuation Ratio
P/S ratio4 6.50 6.04 5.72 4.61 4.53
Benchmarks
P/S Ratio, Competitors5
Amgen Inc. 5.66 4.88 5.78 5.17 5.10
Bristol-Myers Squibb Co. 2.53 2.36 2.19 3.29 3.16
Danaher Corp. 6.02 6.23 7.76 5.79 6.37
Eli Lilly & Co. 15.03 18.25 20.77 10.96 8.01
Gilead Sciences Inc. 6.34 4.98 3.40 3.86 2.85
Johnson & Johnson 6.16 4.26 4.43 4.34 4.66
Merck & Co. Inc. 4.71 3.60 5.43 4.71 3.96
Pfizer Inc. 2.46 2.32 2.61 2.35 3.15
Regeneron Pharmaceuticals Inc. 5.71 5.52 7.84 7.01 4.20
Thermo Fisher Scientific Inc. 4.34 4.73 4.99 4.73 5.39
Vertex Pharmaceuticals Inc. 10.40 10.78 11.16 8.56 8.21
P/S Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 6.24 5.55 5.89 4.56 4.50
P/S Ratio, Industry
Health Care 3.34 3.36 3.52 3.11 3.28

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Data adjusted for splits and stock dividends.

2 2025 Calculation
Sales per share = Net revenues ÷ No. shares of common stock outstanding
= 61,160,000,000 ÷ 1,768,169,012 = 34.59

3 Closing price as at the filing date of AbbVie Inc. Annual Report.

4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= 224.81 ÷ 34.59 = 6.50

5 Click competitor name to see calculations.


The price to sales ratio exhibited an increasing trend over the five-year period. Share price and sales per share both demonstrated fluctuations, but their combined effect resulted in a consistent rise in the P/S ratio.

Share Price
The share price increased from US$144.03 in 2021 to US$224.81 in 2025. Growth was not linear, with a more substantial increase observed between 2023 and 2025 (approximately 28%) compared to the earlier periods.
Sales per Share
Sales per share showed a slight increase from US$31.77 in 2021 to US$32.81 in 2022, followed by a decrease to US$30.75 in 2023. It then recovered to US$31.91 in 2024 and continued to rise to US$34.59 in 2025. This indicates some volatility in sales performance relative to the number of outstanding shares.
Price to Sales Ratio
The P/S ratio began at 4.53 in 2021 and increased to 6.50 in 2025. The largest single-year increase occurred between 2022 and 2023, moving from 4.61 to 5.72. The increase from 2024 to 2025 was more moderate, at 6.04 to 6.50. This suggests that the market valuation, relative to sales, has been steadily increasing over the period, with a notable acceleration in 2023.

The observed trend in the P/S ratio suggests a growing investor confidence in the company’s ability to generate sales, or a willingness to pay a higher premium for each dollar of sales. The interplay between share price appreciation and fluctuations in sales per share has driven this overall increase.

AI Ask an analyst for more


Price to Book Value (P/BV)

AbbVie Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
No. shares of common stock outstanding1 1,768,169,012 1,765,354,859 1,766,473,359 1,769,399,971 1,768,753,829
Selected Financial Data (US$)
Stockholders’ equity (deficit) (in millions) (3,270) 3,325 10,360 17,254 15,408
Book value per share (BVPS)2 -1.85 1.88 5.86 9.75 8.71
Share price1, 3 224.81 192.87 175.75 151.31 144.03
Valuation Ratio
P/BV ratio4 102.40 29.97 15.52 16.53
Benchmarks
P/BV Ratio, Competitors5
Amgen Inc. 22.99 26.61 24.94 35.01 18.51
Bristol-Myers Squibb Co. 6.61 6.98 3.35 4.88 4.07
Danaher Corp. 2.82 3.00 3.47 3.64 4.16
Eli Lilly & Co. 36.91 57.93 65.80 29.36 25.28
Gilead Sciences Inc. 8.07 7.36 4.01 4.90 3.65
Johnson & Johnson 7.12 5.30 5.48 5.37 5.90
Merck & Co. Inc. 5.82 4.99 8.68 6.07 5.05
Pfizer Inc. 1.78 1.68 1.75 2.48 3.35
Regeneron Pharmaceuticals Inc. 2.62 2.67 3.96 3.77 3.60
Thermo Fisher Scientific Inc. 3.62 4.09 4.57 4.83 5.18
Vertex Pharmaceuticals Inc. 6.69 7.24 6.26 5.50 6.16
P/BV Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 7.72 7.03 6.77 5.66 5.72
P/BV Ratio, Industry
Health Care 6.08 5.99 5.94 5.26 5.48

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Data adjusted for splits and stock dividends.

2 2025 Calculation
BVPS = Stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= -3,270,000,000 ÷ 1,768,169,012 = -1.85

3 Closing price as at the filing date of AbbVie Inc. Annual Report.

4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= 224.81 ÷ -1.85 =

5 Click competitor name to see calculations.


The price to book value (P/BV) ratio exhibits a volatile pattern over the observed period. Initially, the ratio decreased from 16.53 in 2021 to 15.52 in 2022, suggesting a relative convergence between share price and book value per share during that time. However, a significant increase is then observed, with the P/BV ratio rising to 29.97 in 2023 and escalating dramatically to 102.40 in 2024. The book value per share experienced a substantial decline during this period, contributing to the increasing P/BV ratio. The final year presented shows a negative book value per share, resulting in an undefined P/BV ratio.

Share Price Trend
The share price demonstrates a consistent upward trend throughout the period, increasing from US$144.03 in 2021 to US$224.81 in 2025. This indicates positive market sentiment or growth expectations regarding the company’s stock.
Book Value Per Share Trend
Book value per share decreased significantly from US$8.71 in 2021 to US$5.86 in 2023. This decline accelerated in 2024, falling to US$1.88, and culminating in a negative value of US$-1.85 in 2025. This substantial reduction in book value is a key driver of the observed changes in the P/BV ratio.
P/BV Ratio Interpretation
The initial P/BV values suggest the market valued the company at approximately 15 to 16 times its book value. The subsequent surge in the ratio, particularly in 2024, indicates a substantial premium placed on the company’s stock relative to its net asset value. The negative book value in 2025 renders the P/BV ratio meaningless, as it represents a division by zero or a negative number, and suggests significant accumulated losses or other factors eroding shareholder equity.

The dramatic increase in the P/BV ratio, coupled with the declining and ultimately negative book value per share, warrants further investigation. Potential causes could include share repurchases, significant write-downs of assets, or substantial losses impacting equity. The negative book value per share in the final year is a particularly noteworthy development requiring detailed analysis.

AI Ask an analyst for more